You just read:

Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated with Ibrutinib, Including Those with High-Risk Disease, with Up to Four Years of Follow-Up

News provided by

Janssen Research and Development LLC

Jun 05, 2017, 07:05 ET